Top Globe News – Lifestyle
Author:
PulseSight Therapeutics S.A.S
Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026
May 11, 2026
Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
April 29, 2026